Viking shares sink as obesity pill misses expectations in key study
The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Viking’s drug.
Previous Post
CSL to separate vaccine business, cut jobs
Next Post
FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago